FDA lifts clinical hold on Aardvark Therapeutics’ ARD-101 for Prader-Willi syndrome

Bitget2026/10/22 20:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA lifted the clinical hold on Aardvark Therapeutics’ ARD-101 for hyperphagia in Prader-Willi syndrome, allowing clinical development to resume.
Resumption of patient trials remains subject to further FDA engagement on Phase 3 trial design.
The FDA imposed the hold in May 2026 following reversible ECG changes in healthy volunteers.
A subsequent healthy-volunteer ECG study found no cardiac events at ARD-101 doses of 200 mg and 400 mg twice daily.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610221605PRIMZONEFULLFEED9851574) on October 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

FDA lifts clinical hold on Aardvark Therapeutics’ ARD-101 for Prader-Willi syndrome

You may also like

Crypto prices